Clinical trial reportInvestigational new drugsPublished
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors
Regional connection
Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source
- Institutions
- Fox Chase Cancer Center, Temple Health
- County
- Philadelphia County
Publication record
- Type
- Clinical trial report
- Venue
- Investigational new drugs
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Neoplasms; Antineoplastic Agents, Alkylating; Maximum Tolerated Dose; Dose-Response Relationship, Drug; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male; DNA damage
- PubMed ID
- 42410111
- Added to directory
- Source checked